Cyclazodone

Standard Drug Panel Inclusion

Cyclazodone is a cyclopentyl-substituted aminorex derivative that is not detected on standard immunoassay drug screens. Its oxazolinone ring structure is distinct from amphetamines, and cross-reactivity with standard panels is not expected. However, cyclazodone is metabolized to pemoline-related compounds, and some extended panels that screen for pemoline metabolites may show cross-reactivity.

Urine Detection

Cyclazodone and its metabolites can be detected in urine for approximately 2 to 5 days. Metabolism involves ring-opening and oxidative pathways. The metabolic relationship to pemoline and aminorex creates a complex metabolite profile. Standard immunoassay screens are unreliable for cyclazodone detection.

Blood and Saliva Detection

Blood concentrations are detectable for approximately 12 to 48 hours. Oral fluid testing has not been specifically validated for cyclazodone. Clinical and forensic detection relies on instrumental analysis.

Hair Follicle Detection

Hair testing for cyclazodone requires specialized analytical methods. No standard commercial panels include this compound.

Confirmatory Testing

LC-MS/MS is the definitive method for cyclazodone identification. The oxazolinone ring produces characteristic fragmentation. Analysis should target both the parent compound and pemoline-related metabolites for comprehensive detection.

Reagent Testing

Marquis reagent typically shows no reaction or a faint color change with cyclazodone. Mecke and Mandelin reagents produce minimal responses. Reagent testing is insufficient for identification of this compound.

Liver Monitoring

This is the distinctive harm reduction recommendation for cyclazodone: periodic liver function testing. The pemoline hepatotoxicity history creates a genuine obligation to monitor. At minimum, establish a baseline before use and test again after regular use.

Low Dose Protocol

Given the 3–5x potency increase over pemoline:

• Pemoline therapeutic doses were 18.75–112.5 mg/day
• Cyclazodone equivalent doses would be approximately 4–40 mg
• Starting at 2–5 mg is appropriate given the absence of human data

Avoid Alcohol and Other Hepatotoxic Substances

Given hepatotoxicity concerns, alcohol co-administration is particularly inadvisable. Also avoid other hepatotoxic substances (e.g., acetaminophen at high doses, certain supplements).

Limit Duration of Use

Pemoline's hepatotoxicity was associated with both acute and cumulative use. Avoid prolonged daily use courses. Cycle on/off with liver monitoring.

Drug Interactions

• MAOIs — Avoid; elevated dopaminergic stimulation risk
• Other stimulants — Additive CNS and cardiovascular stress
• Hepatotoxic drugs — Avoid; additive liver risk

Hepatotoxicity — Primary Concern

The critical risk associated with cyclazodone is inherited from its parent compound pemoline: hepatotoxicity. Pemoline was withdrawn from the US market in 2005 by Abbott Laboratories due to 13 cases of acute liver failure (including deaths) that exceeded expected background rates. The mechanism is not fully characterized but may involve reactive metabolite formation.

Whether this hepatotoxicity risk is shared by cyclazodone specifically is unknown. The structural modification (cyclopropyl) may alter metabolic pathways and change the hepatotoxicity profile — but this is speculative. Given pemoline's documented serious hepatotoxic events, cyclazodone users should treat hepatotoxicity as a genuine potential risk.

Monitoring Recommendations

Given the pemoline precedent, liver function monitoring (ALT/AST) during regular cyclazodone use is a reasonable precaution. Jaundice, abdominal pain (right upper quadrant), dark urine, or unusual fatigue warrant immediate cessation and medical evaluation.

Cardiovascular Risk

The minimal noradrenergic activity of pemoline-class compounds translates to lower cardiovascular stimulation than amphetamines — a relative safety advantage for cardiac risk. However, high doses can still produce elevated heart rate.

Reddit Context on Excitotoxicity

A Reddit post discussing excitotoxicity risks "with stronger nootropics, particularly research chemicals" and specifically mentioning cyclazodone reflects community awareness of multiple potential mechanisms of harm. Excitotoxic risk is not a well-established primary concern for dopaminergic stimulants at typical doses, but represents community-level prudence about unknown risks.

Cyclazodone is currently a gray area compound within all parts of the world, meaning its regulation lies in a legal gray area and that it is not known to be specifically illegal ("scheduled") within any country. However, people may still be charged for its possession under certain circumstances such as under analogue laws and with intent to sell or consume. It is a banned stimulant under the World Anti-Doping Agency prohibited list.

• Germany: Cyclazodone is not a controlled substance under the BtMG (Narcotics Act) or the NpSG (New Psychoactive Substances Act). According to §2 AMG (Medicines Act) it would fall under the definition of a medicine because it induces pharmacological effect. By a decision of the European Court of Justice, this definition was declared ineffective because it was not compatible with EU law. Cyclazodone can be considered legal.

• Switzerland: Cyclazodone is not controlled under Buchstabe A, B, C and D. It could be considered legal.

• United States: Cyclazodone being an analogue of pemoline, a Schedule IV controlled substance in the US, may fall under Federal Analogue Act, 21 U.S.C. § 813 when intended for human consumption.

• Responsible use

• Research chemicals

• Stimulants

• Releasing agent

• Amphetamine

• 4-Methylaminorex

• Cyclazodone (Wikipedia)

• Cyclazodone (Isomer Design)

• Segal, D. S., Cox Jr, R. H., Stern, W. C., & Maickel, R. P. (1967). Stimulatory effects of pemoline and cyclopropylpemoline on continuous avoidance behavior: similarity to effects of D-amphetamine. Life Sciences, 6(23), 2567-2572. https://doi.org/10.1016/0024-3205(67)90322-0